Brief: Regenxbio Reports New Positive Interim Data From Phase I/II Affinity Duchenne® Trial Of Rgx-202
11/03/2026 16:48
March 11 (Reuters) - Regenxbio Inc RGNX.O: REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 REGENXBIO INC - NO SERIOUS ADVERSE EVENTS OBSERVED IN PHASE I/II STUDY REGENXBIO INC - PIVOTAL TOPLINE DATA EXPECTED IN Q2 2026 REGENXBIO INC - TO REQUEST PRE-BLA MEETING WITH FDA IN MID-2026 Source text: ID:nPn3HL4bwa Further company coverage: RGNX.O ((Reuters.Briefs@thomsonreuters.com;))